TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02486250

Intervention type: OTHER
Intervention: Validation Study

Intervention type: OTHER
Intervention: Validation Study

Intervention type: OTHER
Intervention: Validation Study
Study: NCT03042130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: standard of care

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Carboxymaltose
Description: Two IV doses
Study: NCT01978626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App modules

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CBT-I
Study: NCT06301139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goat milk-based infant formula
Description: Infant formula based on goat milk for 4 weeks at volume depending on the infant

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cow's milk-based infant formula with probiotic drops
Description: Infant formula based on cow's milk with probiotic Lactobacillus reuteri drops for 4 weeks at volume depending on the infant
Study: NCT02619721

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PINS SNS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINS SNS
Study: NCT04804150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum suspension system active or inactive
Description: The device will be plugged in, or won't be plugged in, depending of the randomization. The patient and the investigator will not know whether the device is plugged in or not, and if the medical device is active or not
Study: NCT05073198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education brochure
Description: In the content of the brochure about testicular cancer and CCTM prepared in line with the literature; It includes information such as the definition of testicular cancer, testicular cancer risk factors and symptoms, the importance of early diagnosis in testicular cancer, how CCTM is performed, and what to do in case of differences after the examination. Expert opinion was obtained from three faculty members (a professor from the Department of Urology, a professor in Public Health Nursing and a physician faculty member) regarding the content validity of the educational brochure created before the research.
Study: NCT04621487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 14 days 1 gr bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 14 days 500 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 14 days 500 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: 40 mg bid 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: according to antibiogram
Description: according to antibiogram
Study: NCT01953900

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GD2 T cells
Description: On dose levels 1 and 2 each patient receives one injection of GD2 T cells followed by VZV vaccine injection 42 days later.~Dose Level 1: 1x10\^6 cells/m\^2~Dose Level 2: 1x10\^7 cells/m\^2~The next dose levels to be studied following Dose level 2 are Dose levels 7 and 8 where subjects will receive the VZV vaccine followed by a single infusion of iC9-GD2-CAR-VZV-CTLs within 48 hours after VZV vaccine:~Dose Level 7: 1 x 10\^7 cells/m2~Dose Level 8: 1 x 10\^8 cells/m\^2~Dose levels 9-11 will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine prior to administration of the T cells.~Dose Level 9: 1 x 10\^8 cells/m\^2~Dose Level 10: 5 x 10\^8 cells/m\^2~Dose Level 11: 1 x 10\^9 cells/m\^2~The previously planned dose levels 3-6 will not be studied.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VZV vaccine
Description: Subjects will receive a VZV vaccine with CTL infusion within 48 hours after the vaccine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
Study: NCT04619355

Intervention type: DEVICE
Intervention: NIRS-IVUS
Description: Near-infrared spectroscopy-intravascular ultrasound can be implemented in parallel with intravascular ultrasound and provides important information for predicting prognosis by measuring the lipid component of atherosclerotic plaques.
Study: NCT02654665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Diet and exercise designed for 5-7% weight loss over 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: GLP-1 agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: GLP-1 agonist
Study: NCT00165542

Intervention type: OTHER
Intervention: A PROTEIN level
Study: NCT04461015

Intervention type: DRUG
Group type: OTHER
Intervention: 0.8mU Insulin followed by withdrawal period followed by 0.4mU study
Description: Clamp study with insulin infused at 0.8 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.4 mU/Kg/min
Study: NCT00893269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramelteon
Description: ramelteon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: zolpidem
Study: NCT04320823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Updated Plasma Collection Feature
Description: Plasma collection using a novel, patented system that supports a more individualized collection approach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Current Plasma Collection Approach
Description: Plasma collection using the current collection approach.
Study: NCT06319040

Intervention type: OTHER
Intervention: Muscle strength measurement
Description: Muscle strength of both legs, maximal reciprocal concentric isokinetic knee extension (quadriceps) and flexion (hamstring) at 60°/s, 90°/s and 180°/s speeds were evaluated

Intervention type: OTHER
Intervention: Muscle strength measurement
Description: Muscle strength of both legs, maximal reciprocal concentric isokinetic knee extension (quadriceps) and flexion (hamstring) at 60°/s, 90°/s and 180°/s speeds were evaluated
Study: NCT03612843

Intervention type: OTHER
Intervention: Observational dry needle
Description: No intervention provided by the study. Observation of any adverse events that occur surrounding dry needling by a physical therapist.
Study: NCT06319040

Intervention type: OTHER
Intervention: Muscle strength measurement
Description: Muscle strength of both legs, maximal reciprocal concentric isokinetic knee extension (quadriceps) and flexion (hamstring) at 60°/s, 90°/s and 180°/s speeds were evaluated

Intervention type: OTHER
Intervention: Knee joint proprioception
Description: Knee joint proprioception was assessed by joint position sense. Joint position sense was measured by the previously taught ability to actively find joint position (EPAB)

Intervention type: OTHER
Intervention: Knee joint proprioception
Description: Knee joint proprioception was assessed by joint position sense. Joint position sense was measured by the previously taught ability to actively find joint position (EPAB)

Intervention type: OTHER
Intervention: Knee joint proprioception
Description: Knee joint proprioception was assessed by joint position sense. Joint position sense was measured by the previously taught ability to actively find joint position (EPAB)

Intervention type: OTHER
Intervention: Balance
Description: The patients and healthy individuals participating in our study were evaluated with the General Stability Index (GSI) for general balance ability, Anterior-Posterior Stability Index (APSI) for anterior-posterior balance ability, Medial-Lateral Stability Index (MLSI) for lateral balance ability and Fall Risk Index (DRI) and Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk. High values obtained indicate deterioration in balance and increased risk of falling.

Intervention type: OTHER
Intervention: Balance
Description: The patients and healthy individuals participating in our study were evaluated with the General Stability Index (GSI) for general balance ability, Anterior-Posterior Stability Index (APSI) for anterior-posterior balance ability, Medial-Lateral Stability Index (MLSI) for lateral balance ability and Fall Risk Index (DRI) and Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk. High values obtained indicate deterioration in balance and increased risk of falling.
Study: NCT01779505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
Study: NCT03899584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-Aminopyridine
Description: Each patient will take 10 mg per kilogram of weight (example: a person weighing 60 kg, will take two capsules three times a day after meals, for a total of 6 capsules / day). Each capsule will contain 10 milligrams of 4-Aminopyridine that will allow to be administered sequentially at progressively higher doses / day. The dose of 4-aminopyridine will increase 10 mg / 2 to 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo arm will include a placebo of microcrystalline cellulose.
Study: NCT01779505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
Study: NCT00754091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer based lubricating liquid
Description: three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
Study: NCT03562416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib (BIBF 1120, Ofev)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study: NCT00840060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AMALS
Description: Addressing multiple aspects of language simultaneously

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DTA
Description: Discrete Trial Approach
Study: NCT00106574

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks
Study: NCT02406729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue 1,2,3,4 (attenuated) vaccine
Description: Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Route:subcutaneous
Study: NCT03143998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5172A
Description: A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5172A
Description: A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5172A
Description: A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5172A
Description: A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
Study: NCT00784485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair injections
Description: In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
Study: NCT00556179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoserum (Dermacyd Femina®)
Description: Once a day during three months
Study: NCT02046694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: At week 1, patients will begin allopurinol daily (100 mg for weight \>30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
Study: NCT00340379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Target dosage 120-160mg/day based on tolerance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Target dosage 150-200mg/day based on tolerance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Target dosage 6-8mg/day based on tolerance.
Study: NCT06319040

Intervention type: OTHER
Intervention: Balance
Description: The patients and healthy individuals participating in our study were evaluated with the General Stability Index (GSI) for general balance ability, Anterior-Posterior Stability Index (APSI) for anterior-posterior balance ability, Medial-Lateral Stability Index (MLSI) for lateral balance ability and Fall Risk Index (DRI) and Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk. High values obtained indicate deterioration in balance and increased risk of falling.

Intervention type: OTHER
Intervention: Fall risk test
Description: Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk
Study: NCT00469326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: two days 80mg atorvastatin pre-treatment before PCI

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Atorvastatin
Description: two days 80mg atorvastatin pre-treatment before PCI
Study: NCT04265274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: dosing 400mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbin
Description: 25mg/m2 day 1 and 8,
Study: NCT06319040

Intervention type: OTHER
Intervention: Fall risk test
Description: Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk
Study: NCT04265274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper
Description: 2 mg of elementary Copper daily
Study: NCT04631653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeriSee®
Description: Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®
Study: NCT04113460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga@work program included physical movements, yoga posture, breathing exercise, pranayama and yoga chants. Session with trainer was conducted on worksite once a week for an hour.
Study: NCT00700583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination therapy of terazosin and hydrochlorothiazide
Description: 25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
Study: NCT04592900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance exercising
Description: selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance exercising
Description: selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance exercising
Description: selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
Study: NCT03885713

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
Description: Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)) per clinical practice or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)) per clinical practice or tofacitinib (oral 5mg bid)
Study: NCT00380419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Description: IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
Study: NCT00869830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biofeedback therapy
Description: biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
Study: NCT02971241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intergenerational Mobile Technology Opportunities Program
Description: The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intergenerational Mobile Technology Opportunities Program
Description: The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
Study: NCT02984449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre+post-operative Cardiac rehabilitation
Description: CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Cardiac rehabilitation
Description: CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
Study: NCT00411190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacatib
Description: Subjects will administer 60 or 120 mg tablets in Session 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin will be administered orally
Study: NCT01107613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opinion leader educational letter
Description: All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader educational letter sent to the primary care provider outlining the needs of this patient.